With positive momentum into 2024

12/02/24 -"We have integrated the 2023 numbers that have been released. Our 2023 figures mainly suffered from the lower than expected recovery in profitability, which we believe will continue into 2024. Our ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

12/02/24

Download

You may also be interested by these reports :

12/11/25

KWS SAAT SE & Co. KGaA

1Q25/26: Sales lower but EBITDA better than expected by us as well as by the market – FY25/26E guidance confirmed

11/11/25

K+S

K+S reported mixed Q3 2025 results, with sales supported by strong pricing and EBITDA benefiting from a low base, although sales missed expectations. ...

10/11/25

Solvay

Solvay remained under pressure in Q3 2025 amid persistent macroeconomic headwinds. Chinese overcapacity continued to weigh on soda ash sales, though ...

07/11/25

Arkema

Arkema’s Q3 2025 results were a mixed bag. Investor sentiment is likely supported by guidance matching consensus and management’s optimistic ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Yara International